Senate Judiciary Committee sends five pharma-related bills to the floor
The Senate Judiciary Committee on Thursday advanced five bills via voice vote that will prohibit and slow some of the games pharma companies often play to extend their monopolies before generic competition comes to market.
One of the five bills aims to preserve generic drug and biosimilar access by prohibiting brand-name drug companies from paying generic drug companies to delay the market entry of competition. While these so-called “pay-for-delay” deals have declined in recent years, pharma companies like Novartis recently paid $245 million to settle allegations of such a deal for its blood pressure drug Exforge.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
